Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 3972 Prostate cancer (CaP) commonly metastasizes to bone resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlined, possibly prerequisite, osteoclastic activities at the bone metastatic sites. We have previously demonstrated that blocking receptor activator of NFκB ligand (RANKL) partially prevent the establishment of CaP in bone and diminishes the progression of CaP growth in the skeleton in murine models. However, RANKL in the serum from CaP patients or from the bone marrow of tumor sites in animal models or in the cell lines used in those studies was at very low level. These findings strongly suggest that soluble factors other than RANKL may mediate the tumor-induced osteclast activity. To identify these factors we first used a human cytokine antibody array (174 cytokines) to measure cytokine protein expression in conditioned medium (CM) collected from CaP cells LNCaP and C4-2B (the derivative from LNCaP but with bone metastastatic characteristics). We found that both cells produced significantly high amount of several cytokines such as IL-8 and MCP-1, but not IL-6, IL-11, TNFα, MIP-1α, and RANTES. Furthermore, IGFBP-2 and MMP-9 were found significantly higher in C4-2B CM than LNCaP CM. (4.4-fold for IGFBP-2 and 3.1-fold for MMP-9). These results were confirmed by using ELISA. Finally, murine osteoclast precursor RAW264.7, cells or human bone marrow-derived monocytes were cultured with LNCaP CM (10%). Within 24 hours, LNCaP-CM induced multinucleated TRAP positive osteoclast formation from RAW264.7 cells while the soluble RANKL (50ng/ml) required 96 hours to form mature osteoclasts. Recombinant human IL-8 (10ng/ml), but not MCP-1 (10ng/ml), directly stimulated Raw 264.7 differentiation into mature osteoclast and bone resorption on dentin slices within 6 days of culture in the absence of RANKL. LNCaP-CM-induced osteoclast formation and bone resorption from RAW264.7 cells and human bone marrow-derived monocytes (HBMC) were dose-dependently inhibited by adding anti-IL-8 neutralizing antibody and further synergistically inhibited with addition of MCP-1 antibody in HBMC. In summary, we have identified IL-8 and MCP-1 that produced by CaP cells directly induce osteoclastogenesis and bone resorption in vitro. Together with recent report that serum IL-8 level is elevated in men with CaP and bone metastases and MCP-1 as a key mediator involved in the recruitment of monocytes/macrophages in inflamed bone, this study may provide a targeting strategy for the treatment of CaP skeletal metastasis.

Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone

Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption

CRABP2 Promotes Cell Migration and Invasion by Activating PI3K/AKT and MAPK Signalling Pathways Via Upregulating LAMB3 in Prostate Cancer

PTHrP‐induced MCP‐1 Production by Human Bone Marrow Endothelial Cells and Osteoblasts Promotes Osteoclast Differentiation and Prostate Cancer Cell Proliferation and Invasion in Vitro

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone

Monocyte Chemoattractant Protein-1 Modulates Invasion and Apoptosis of Pc-3m Prostate Cancer Cells Via Regulating Expression of Vegf, Mmp9 and Caspase-3

Monocyte Chemotactic Protein-1 (MCP-1) Acts As a Paracrine and Autocrine Factor for Prostate Cancer Growth and Invasion

Prostate Cancer Cells Induce Osteoclastogenesis And Bone Resorption Through Rankl-Independent Interleukin-8 (Il-8) And Monocyte Chemoattractant Protein-1 (Mcp-1) Production

Monocyte Chemotactic Protein-1 Promotes the Proliferation and Invasion of Osteosarcoma Cells and Upregulates the Expression of Akt

Abstract 303: Host-derived CCL2 plays a critical role in prostate cancer growth and skeletal metastasis

Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo

Abstract 5387: Host-derived CCL2 drives prostate cancer bone metastasis via CCND2/STAT3 pathway

Ccr2 Expression Correlates With Prostate Cancer Progression

Cxcr6 Is Expressed In Human Prostate Cancer In Vivo And Is Involved In The In Vitro Invasion Of Pc3 And Lncap Cells

CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway

Lung Cancer Metastasis-Related Protein 1 Promotes the Transferring from Advanced Metastatic Prostate Cancer to Castration-Resistant Prostate Cancer by Activating the Glucocorticoid Receptor Α Signal Pathway.

Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway

Sdf-1/Cxcr4 Axis Promotes Prostate Cancer Cell Invasion And Bone Metastasis Through P38, Nf-Kappa B And Hif-1 Alpha Pathways

Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion